Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 30, 2006Hepatology

Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response

View Full Paper
Ask AI
Bookmark
Share

Authors

MBMartijn J. ter BorgRadboud University NijmegenMZMonika van ZonneveldErasmus MC
Stefan Zeuzem
Stefan ZeuzemUniversité Claude Bernard Lyon 1

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Borg et al. (2006) studied this question.

synapsesocial.com/papers/6a9ca4e4c6c6e28b8d02fd95https://doi.org/10.1002/hep.21302
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B2005 · 1,526 citations
  2. 2A Viral Kinetic Study Using Pegylated Interferon Alfa-2b and/or Lamivudine in Patients With Chronic Hepatitis B/HBeAg Negative *2005 · 39 citations
  3. 3Extended Lamivudine Treatment in Patients With Chronic Hepatitis B Enhances Hepatitis B E Antigen Seroconversion Rates: Results After 3 Years of Therapy2001 · 626 citations
  4. 4Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea2000 · 337 citations
  5. 5Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B2002 · 304 citations